NOVARTIS FARMA - PRODUTOS FARMACEUTICOS, S.A. secures contract for Adcm 4825 25 - Acquisition Of The Medication Tisagenlecleucel 12 X10e6 - 6 X10e8 Cells Disp Inj Fr 50 Ml Iv

Portugal, April 13 -- Portugal based NOVARTIS FARMA - PRODUTOS FARMACEUTICOS, S.A. has secured contract from Ipo Porto Fg, Epe for Adcm 4825 25 - Acquisition Of The Medication Tisagenlecleucel 12 X10e6 - 6 X10e8 Cells Disp Inj Fr 50 Ml Iv. The value of the contract is worth 631892500 EUR.

Published by HT Digital Content Services with permission from Pivotal Sources....